Ein Verfahren zur Arzneimittelüberwachung nach ihrer Zulassung

  • J. Hillebrand
Conference paper
Part of the Lecture Notes in Medical Informatics book series (LNMED, volume 5)


It has been generally recognized that safety and efficiency tests for drugs are not completed with their admission onto the market. Many undesirable side effects have only been recognized during practical application, such as, for example, in the case of Contergan. Therefore, preventive measures must be taken so that, in case any suspicions arise data for closer checking is available.


Undesirable Side Effect Close Check Nicht Nach Monitoring Nurse Intensive Drug Monitoring 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Online Conferences Ltd., Uxbridge, England 1979

Authors and Affiliations

  • J. Hillebrand
    • 1
  1. 1.Institut für klin. Pharmakologie der FUKlinikum SteglitzBerlinDeutschland

Personalised recommendations